This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Nuvilex's Subsidiary, Medical Marijuana Sciences, Inc., To Develop Disease Treatments Based On Cannabinoids

SILVER SPRING, Md., Feb. 12, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for the treatment of human diseases, announced today its subsidiary, Medical Marijuana Sciences, Inc., will develop treatments for human diseases by employing cannabinoids from marijuana (Cannabis sativa).

The use of Cannabis for medicinal purposes dates back more than 3,000 years. It was introduced into Western medicine in the 1840s. Its analgesic, sedative, anti-inflammatory, anticonvulsant, and antispasmodic effects formed the original basis for its use. The components of marijuana that have shown medical activity are known as "cannabinoids", approximately 70 cannabinoids of which have been found in Cannabis sativa.

Cannabinoids can be classified into three groups: (1) naturally-occurring cannabinoids – examples are Delta 9- tetrahydrocannabinol (THC) and cannabidiol (CBD); (2) endocannabinoids – these are synthesized "on demand" within the body by particular types of cells - examples include anandamide (AEA) and 2-arachidonoyl-glycerol (2-AG); (3) synthetic cannabinoids – an example is nabilone, which has been approved by the U.S. Food and Drug Administration for the treatment of cancer-related side effects.

Since the 1970s, cannabinoids have been known to alleviate pain, nausea, and vomiting. These compounds have been particularly effective against cancer-related pain and in enhancing the appetites of cancer patients which are typically diminished. The latter discovery has led to finding that cannabinoids can help relieve cancer-related cachexia, a "wasting" syndrome composed of weight loss, muscle atrophy, fatigue, weakness, and loss of appetite.

"Cannabinoids have been investigated both in vivo and in vitro for many years targeting a wide array of diseases and disorders, thus amassing a large portfolio of promising research data," said Dr. Gerald Crabtree, Chief Operating Officer of Nuvilex.  "Naturally-occurring cannabinoids such as THC and CBD are excellent cornerstones upon which our subsidiary, Medical Marijuana Sciences, Inc. can build disease treatments. There have been many reports in scientific journals and other literature that contribute to our understanding of how these marijuana constituents work, as well as reports of their activity against various diseases in preclinical test systems. We intend to use our expertise to establish ourselves as a leading contributor to the growing database of information demonstrating the therapeutic benefits of cannabinoids in a clinical setting."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs